
    
      An Open-label, Single-center, 2-Part, Randomized Study to Assess the Pharmacokinetics of R406
      in Healthy Subjects when Fostamatinib 150 mg is Administered Alone in Fed and Fasted state
      and in Combination with Ranitidine in Fasted State, and to Assess the Relative
      Bioavailability of Process Variants of Tablets
    
  